Coloplast AS (OCSE:COLO B) EPS (Basic): kr9.34 (TTM As of Mar. 2026)


OCSE:COLO B Coloplast AS OCSE:COLO B
75 GF Score
Price kr379.00
GF Value kr835.58
Valuation Significantly Undervalued
! 7 Warning Signs
View Full Analysis

What is Coloplast AS EPS (Basic)?

Coloplast AS OCSE:COLO B +0.88% 75 EPS (Basic) is kr9.34 as of Mar. 2026. GuruFocus rates OCSE:COLO B with a GF Score™ of 75/100 and a GF Value™ of kr835.58 (Significantly Undervalued). The stock has 7 warning signs investors should review.

Coloplast AS's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was kr-4.31. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was kr9.34.

Coloplast AS's EPS (Diluted) for the three months ended in Mar. 2026 was kr-4.31. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was kr9.34.

Coloplast AS's EPS without NRI for the three months ended in Mar. 2026 was kr6.16. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 23.49.

During the past 12 months, Coloplast AS's average EPS without NRIGrowth Rate was 15.10% per year. During the past 3 years, the average EPS without NRI Growth Rate was -1.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 1.60% per year. During the past 10 years, the average EPS without NRI Growth Rate was 4.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Coloplast AS's highest 3-Year average EPS without NRI Growth Rate was 56.10% per year. The lowest was -9.80% per year. And the median was 6.60% per year.

Coloplast AS  (OCSE:COLO B) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Coloplast AS EPS (Basic) Related Terms

Coloplast AS EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Coloplast AS's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Coloplast AS EPS (Basic) Chart

Coloplast AS Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.67 22.14 22.21 22.46 16.13

Coloplast AS Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.05 3.57 3.88 6.20 -4.31
OCSE:COLO B
75GF Score
Coloplast AS OCSE:COLO B
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Coloplast AS EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Coloplast AS's Basic EPS for the fiscal year that ended in Sep. 2025 is calculated as

Basic EPS (A: Sep. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(3636-0)/225.400
=16.13

Coloplast AS's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-971-0)/225.200
=-4.31

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr9.34

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of kr9.34 mean?
Coloplast AS (OCSE:COLO B) has a EPS (Basic) of kr9.34 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Coloplast AS and its competitors.
Is Coloplast AS's EPS (Basic) too high?
Coloplast AS's current EPS (Basic) is kr9.34. Overall, Coloplast AS has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Coloplast AS's EPS (Basic) compare to ISRG and BDX?
Coloplast AS's EPS (Basic) of kr9.34 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Devices & Instruments company?
A good EPS (Basic) depends on the Medical Devices & Instruments industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Coloplast AS and its competitors. Coloplast AS's current EPS (Basic) is kr9.34. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coloplast AS stock overvalued right now?
Based on GuruFocus' analysis, Coloplast AS (OCSE:COLO B) is currently considered Significantly Undervalued. The stock's GF Value™ is kr835.58, compared to a current price of kr379.00 — trading 54.6% below its estimated fair value. The current EPS (Basic) is kr9.34. Coloplast AS's overall GF Score™ is 75/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Coloplast AS (OCSE:COLO B), the current EPS (Basic) is kr9.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Coloplast AS (OCSE:COLO B) Overvalued in 2026?

Based on GuruFocus' analysis, Coloplast AS stock appears to be undervalued. The current stock price of kr379.00 is trading 54.6% below its estimated GF Value™ of kr835.58. GuruFocus considers Coloplast AS to be Significantly Undervalued.

Key valuation signals for OCSE:COLO B:

  • EPS (Basic): kr9.34
  • GF Value™: kr835.58 vs. price of kr379.00 (54.6% below fair value)
  • GF Score™: 75/100 with 7 warning signs

No single metric tells the full story. See the OCSE:COLO B stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Coloplast AS Business Description

Address Holtedam 1-3, Humlebaek, DNK, DK-3050
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, intermittent catheters for continence care, and devices for patients with neck stomas. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
75GF Score

Get the complete analysis for OCSE:COLO B

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr379.00
Price
kr835.58
GF Value